Theravance Biopharma Inc (TBPH) Stock Score, Valuation & Financial Research
Theravance Biopharma Inc is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 70/100.
Quick answer for TBPH
Theravance Biopharma Inc currently has a Wall Street Score of 70/100. The stored market price is $17.03. Its financial score is 40/100. Its valuation score is 100/100. These figures are a research snapshot, not a buy or sell recommendation.
What Theravance Biopharma Inc does
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
TBPH financial snapshot
- Wall Street Score:
- 70/100
- Current price:
- $17.03
- Market capitalization:
- $882.6M
- Revenue:
- $109.8M
- Net income:
- $114.5M
- Free cash flow:
- $238.5M
- Cash:
- $288.1M
- Total debt:
- $73.3M
- EPS:
- 2.10
- P/E ratio:
- 8.1x
- Financial score:
- 40/100
- Valuation score:
- 100/100
- Revenue score:
- 57/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $238.5M, showing positive cash generation.
- The balance sheet shows $288.1M of cash versus $73.3M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 100/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 40/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research TBPH
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.